Q3 2024 Relmada Therapeutics Inc Earnings Call Transcript
Key Points
- Relmada Therapeutics Inc (RLMD) is advancing the development of new treatments for CNS disorders, including major depressive disorder (MDD), with a focus on derisking study design and execution.
- The company expects to report the outcome of the interim analysis for the Reliance II Phase III study by the end of 2024, which could be a significant derisking event for the REL-1017 program.
- Relmada Therapeutics Inc (RLMD) has designed its Phase III registrational program to build on key learnings from previous Phase II and Phase III programs.
- The company is on track to provide the outcome of the planned sample size reestimation interim analysis for the Reliance II study by the end of 2024.
- Relmada Therapeutics Inc (RLMD) has a cash position of approximately $54.1 million as of September 30, 2024, which is expected to support operations through key near-term milestones into 2025.
- Relmada Therapeutics Inc (RLMD) reported a net loss of $21.7 million for the third quarter of 2024, slightly lower than the $22 million loss in the same period of 2023.
- Cash used in operations increased to $16.7 million in the third quarter of 2024 from $11.6 million in the same period of 2023.
- The company's cash, cash equivalents, and short-term investments decreased from $96.3 million at the end of 2023 to $54.1 million as of September 30, 2024.
- The outcome of the interim analysis for the Reliance II study could potentially require the addition of more patients, indicating a need for increased resources and time.
- There is a risk that the Reliance II study could be deemed futile if the drug-placebo delta is below approximately 2.2 points, which would be a setback for the REL-1017 program.
Hello and welcome to the Relmada Therapeutics third quarter, 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question and answer session to ask a question. Please press star one as a reminder, this conference call is being recorded and will be available for replay on the location website.
I would now like to turn the call over to Tim mccarthy from lifesci advisors. Please go ahead Mr mccarthy.
Good day, everyone and thank you for joining us today.
This afternoon, Relmada issued a press release, providing a business update and outlining its financial results for the three months ended, September 30th 2024.
Please note that certain information discussed on the call today is covered under the safe harbor provision of the private securities Litigation Reform Act.
We caution listeners that during this call, Ramadas management team will be making forward-looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
